Background
==========

Diabetes is a chronic, progressive condition that, if not managed properly, can lead to numerous health complications and disability. It has been estimated that approximately 25.8 million people in the United States (US) have diabetes \[[@B1]\]. In adults, 90% to 95% of patients with diabetes have type 2 diabetes mellitus (T2DM), which is characterized by insulin resistance, pancreatic beta-cell dysfunction, and excessive glucose production by the liver. Over the next 40 years, the total prevalence of diabetes in the US is expected to more than double, from 5.6% in 2005 to 12.0% in 2050 \[[@B2]\].

Treatment of T2DM consists of significant lifestyle adjustments and drug therapy, including oral antidiabetic agents and insulin therapy \[[@B3]\]. The American Diabetes Association and the European Association for the Study of Diabetes have agreed that early intervention with metformin should be used in patients with hyperglycemia to help maintain recommended levels of glycemic control \[[@B4]\]. Because T2DM is a progressive disease, timely augmentation of therapy with additional agents, such as insulin, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, and glucagon like peptide-1 receptor agonists, also is recommended \[[@B5]\].

It is well established that the costs attributable to diabetes (including T2DM) are substantial. One recent estimate suggested that the total economic burden of all types of diabetes in the US exceeds \$174 billion annually, which includes \$116 billion in excess medical expenditures and \$58 billion in reduced nation productivity \[[@B6]\]. Medical costs attributed to all types of diabetes include \$27 billion for direct care, \$58 billion to treat patients with diabetes-related chronic complications, and \$31 billion in excess general medical costs \[[@B6]\].

Significant evidence exists showing the relationship between diabetes-related costs and observed glucose values \[[@B7]-[@B12]\]. However, as informative as these studies have been in communicating the economic impact of diabetes, many studies have included data from sources outside the US or did not focus on managed care populations. Further, identifying T2DM patients who could be considered high cost (HC) is of significant interest to health care payers, given the rising health care costs in the US---interventions could be developed that would focus on patients who are likely to become HC and therefore minimize costs of the disease. Previous studies have identified HC patients in other disease areas (e.g., acute coronary syndromes) \[[@B13]\]; but to our knowledge, no retrospective analysis has been published that examines HC patients with T2DM.

The goal of this analysis was to document the actual health care costs incurred by payers for a T2DM population and to determine which factors were associated with patients in the higher tiers of the T2DM cost distribution. Additionally, this study compared health care costs for patients who were identified as HC with patients who were identified as not high cost (NHC).

Methods
=======

This analysis used the LifeLink database (formerly PharMetrics), a commercially available source of computerized administrative claims from 95 managed care health plans covering more than 61 million unique patients. The database included claims from private health plans in all four US geographic regions and had an age and sex distribution representative of national managed care enrollment. The database included patient-level demographics and periods of health plan enrollment; primary and nonprimary diagnoses; detailed information about hospitalizations, diagnostic testing, and therapeutic procedures; inpatient and outpatient physician services; prescription drug use; and cost data in the form of managed-care reimbursement rates for each service. Data are tracked longitudinally within patients via de-identified and unique patient numbers. For the purposes of this analysis, the most recent 5 years of data were used. RTI International's institutional review board determined that this study met all criteria for exemption. Data were available from January 1, 2005, through December 31, 2010.

All patients with at least two diagnoses of T2DM (*International Classification of Diseases, Ninth Revision, Clinical Modification* \[ICD-9-CM\] codes 250.×0 and 250.×2) during the selection window (January 1, 2005, through December 31, 2009) were initially identified for study inclusion. Requiring two T2DM diagnoses helped to rule out patients who may have been suspected of having T2DM but were never formally diagnosed and likely eliminated patients who were miscoded as having T2DM. For each patient identified, his or her index date was defined as the date of the first observed T2DM diagnosis. To allow for adequate follow-up time to address the research questions and to ensure that any observed lack of health care events was the result of no medical activity and not the result of cessation of care, patients were required to have at least 12 months of continuous post-index date observation. Furthermore, to obtain the largest possible sample size of patients with T2DM, we did not require patients to have received a diabetic medication, nor was any pre-index date enrollment required.

Subgroups of patients in the T2DM population were identified as HC or NHC on the basis of where their annual costs fell within the overall T2DM cost distribution. We identified two subgroups of HC T2DM patients a priori: those patients whose costs were in the 90th or greater percentile of all-cause costs and those patients whose costs were in the 80th or greater percentile of all-cause costs. We also identified two subgroups of NHC T2DM patients: those patients whose costs were below the 90th percentile of all-cause costs and those patients whose costs were below the 80th percentile of all-cause costs. We chose to assess both the top 10% and top 20% of patients in the all-cause cost distribution for several reasons. First, it is a well-regarded rule of thumb that the top 20% of patients accrue 80% of health care costs \[[@B14]\]. We wished to evaluate whether this rule held true in a T2DM population. Second, previous studies examining HC patients in other disease areas have used similar methodology \[[@B13]\]. We also felt that it was important to see if patient characteristics changed as we went from the top 20% of patients to the top 10% of patients. For this analysis examining HC and NHC T2DM patients, all-cause costs were examined (rather than T2DM-related costs) because many patients likely had coexisting conditions (e.g., hypertension or renal impairment) that were T2DM related but that may not have been coded as such in the claims.

HC patients then were compared with NHC patients. Key outcome measures that were analyzed included patient characteristics, overall (all-cause) health care resource use and costs, and T2DM-related resource use and costs. All outcome measures presented in this paper were assessed over a 1-year post-index date follow-up period, unless stated otherwise. Patient characteristics that were assessed at the index date included age, sex, geographic region, insurance payer type (i.e., commercial, Medicare, Medicaid, self, Medicare Gap, and missing/unknown), and health plan type (i.e., health maintenance organization, preferred provider organization, point of service, indemnity, and missing/unknown). To assess overall comorbidity burden, we calculated a Charlson Comorbidity Index (CCI) score for each patient over the 1-year follow-up period. The mean CCI score, along with the number and percentage of patients with a score \< 2 or ≥ 2, was reported. The CCI score included 17 categories of comorbidities, as defined by ICD-9-CM diagnosis and procedure codes, with associated weights corresponding to the severity of the comorbid condition of interest \[[@B15]\]. Because all patients in the study had a diagnosis of T2DM and because we wished to evaluate underlying comorbidity burden independent of T2DM, comorbidities corresponding to T2DM were removed from the CCI score (i.e., we did not want the CCI to be inflated for all patients). Antidiabetic agents received were reported by class (i.e., sulfonylureas, meglitinide, biguanide, thiazolidinedione, alpha-glucosidase inhibitor, dipeptidyl peptidase-4, glucagon-like peptide-1, and insulin).

For each patient, overall health care utilization and associated costs were aggregated across all encounters, regardless of reason, observed during the 1-year post-index date period. The following categories of overall health care utilization and costs were evaluated and reported: inpatient, skilled nursing facility, emergency department, outpatient hospital, office visit, laboratory service, other outpatient care, pharmacy, and total health care utilization. For each category of overall health care utilization, the number and percentage of patients with a visit or admission, the mean (standard deviation \[SD\]) number of visits or admissions, and the per-patient costs were reported. Additionally, for patients with an inpatient or skilled nursing facility admission, the average number of days per admission was reported.

The total volume and associated costs of health care services specifically related to T2DM also was reported. Hospital admissions related to T2DM were identified by searching for inpatient hospital confinements in which T2DM was recorded as the primary discharge diagnosis (i.e., ICD-9-CM codes 250.×0 and 250.×2). Office, emergency department, outpatient hospital, other outpatient visits, and laboratory services related to T2DM were identified by searching for medical claims with any diagnosis (i.e., primary or secondary) of T2DM and a relevant place-of-service code for the care setting of interest. Additionally, we evaluated the use and associated costs of all disease-specific medications for which a claim was generated. Medications were identified using appropriate National Drug Codes and Healthcare Common Procedure Coding System codes, brand and generic product names, and therapeutic class descriptions provided in the database.

All analyses were carried out using SAS (Version 9; Cary, North Carolina) statistical software. Descriptive analyses entailed the tabular display of mean and SDs for continuous variables of interest (e.g., total health care costs) and the frequency distribution of categorical variables of interest (e.g., health plan type). All-cause and diabetes-related health care costs were updated to 2011 US dollars, using the medical care component of the US Consumer Price Index.

Logistic regression models were estimated to assess predictors of being an HC patient with T2DM (separate models for the top-10% and the top-20% groups). The dependent variable was a dichotomous (i.e., 0 or 1) variable indicating whether the patient was in the HC cohort. Demographic characteristics that have repeatedly been shown to be associated with costs were used as independent variables and included patient age (i.e., \< 35 years, 35--44 years, and 45--54 years vs. ≥ 55 years), sex (i.e., male vs. female), geographic region (i.e., South, Midwest, and West vs. East), health plan type (i.e., preferred provider organization, point of service, indemnity, and missing/unknown vs. health maintenance organization), and payer type (i.e., Medicaid, Medicare, self, Medicare Gap, and missing/unknown vs. commercial). Clinical variables available in the database were also selected as independent variables and included the CCI score (i.e., CCI score \< 2 vs. CCI score ≥ 2), the types of pharmacologic treatments the patient received (i.e., insulin and oral antidiabetic medications vs. no pharmacological treatment), a diagnosis of renal impairment (i.e., had a renal impairment diagnosis vs. did not have a renal impairment diagnosis), and a diagnosis of obesity (i.e., had an obesity diagnosis vs. did not have an obesity diagnosis). Patients with missing age, sex, health plan, and health payer information were excluded from the regression models.

Results
=======

Among the 1.72 million T2DM patients in the database who met the initial study inclusion and exclusion criteria, 344,019 were identified as being in the top 20% of the cost distribution (i.e., costs \> \$10,901), and 172,004 were identified as being in the top 10% of the cost distribution (i.e., costs \> \$20,528) (Table [1](#T1){ref-type="table"}). Mean (SD) patient age among patients in the top 20% of the cost distribution was 57.2 (13.7) years versus 57.7 (14.9) years among patients in the bottom 80% of the cost distribution. In both the top 20% and the bottom 80% of patients, sex distribution was approximately equal. The mean (SD) CCI score was greater among patients in the top 20% of the cost distribution (3.7 \[2.8\]), than among patients in the bottom 80% of the cost distribution (2.0 \[1.6\]). Chronic pulmonary disease, liver disease, and congestive heart failure were the most common conditions in both cohorts. The percentage of patients receiving oral antidiabetic medications at index date was approximately the same in both cohorts; however, more than twice the percentage of patients in the top 20% of the cost distribution received insulin, compared with patients in the bottom 80% of the cost distribution (8.7% vs. 4.0%).

###### 

Characteristics of the study sample, by cohort

                                             **Cohort**                                                                            
  ------------------------------------------ ------------- --------- ------------- --------- ------------- --------- ------------- ---------
  Total sample                               172,004                 1,548,037               344,019                 1,376,022      
  Age (years)                                                                                                                       
    \< 18                                    1,194         0.69%     17,232        1.11%     3,469         1.01%     14,957        1.09%
    18-25                                    1,445         0.84%     17,163        1.11%     3,269         0.95%     15,339        1.11%
    25-34                                    4,920         2.86%     56,918        3.68%     11,866        3.45%     49,972        3.63%
    35-44                                    14,922        8.68%     164,584       10.63%    31,878        9.27%     147,628       10.73%
    45-54                                    40,506        23.55%    359,704       23.24%    80,397        23.37%    319,813       23.24%
    55-64                                    69,775        40.57%    474,253       30.64%    130,935       38.06%    413,093       30.02%
    ≥ 65                                     39,168        22.77%    457,026       29.52%    82,028        23.84%    414,166       30.10%
    Missing/unknown                          74            0.04%     1,157         0.07%     177           0.05%     1,054         0.08%
    Mean (SD)                                57.46         (12.89)   57.61         (14.82)   57.17         (13.66)   57.7          (14.87)
  Sex                                                                                                                               
    Male                                     86,359        50.21%    789,524       51%       164,587       47.84%    711,296       51.69%
    Female                                   85,630        49.78%    758,425       48.99%    179,402       52.15%    664,653       48.30%
    Missing/unknown                          15            0.01%     88            0.01%     30            0.01%     73            0.01%
  Geographic region                                                                                                                 
    East                                     55,618        32.34%    521,500       33.69%    113,485       32.99%    463,633       33.69%
    South                                    36,130        21.01%    371,487       24%       71,733        20.85%    335,884       24.41%
    Midwest                                  55,462        32.24%    444,249       28.70%    110,809       32.21%    388,902       28.26%
    West                                     24,794        14.41%    210,801       13.62%    47,992        13.95%    187,603       13.63%
  Health plan type                                                                                                                  
    Health maintenance organization          37,332        21.70%    293,868       18.98%    73,580        21.39%    257,620       18.72%
    Preferred provider organization          96,019        55.82%    873,018       56.40%    190,440       55.36%    778,597       56.58%
    Point of service                         23,776        13.82%    178,510       11.53%    45,378        13.19%    156,908       11.40%
    Indemnity                                13,218        7.68%     181,335       11.71%    31,063        9.03%     163,490       11.88%
    Missing/unknown                          1,659         0.96%     21,306        1.38%     3,558         1.03%     19,407        1.41%
  Payer type                                                                                                                        
    Commercial                               125,980       73.24%    1,156,587     74.71%    253,795       73.77%    1,028,772     74.76%
    Medicaid                                 3,154         1.83%     17,382        1.12%     6,019         1.75%     14,517        1.05%
    Medicare                                 18,213        10.59%    91,170        5.89%     31,044        9.02%     78,339        5.69%
    Self                                     19,946        11.60%    213,595       13.80%    42,432        12.33%    191,109       13.89%
    Medicare Gap                             3,987         2.32%     60,944        3.94%     9,317         2.71%     55,614        4.04%
    Missing/unknown                          724           0.42%     8,359         0.54%     1,412         0.41%     7,671         0.56%
  CCI Score^a^                                                                                                                      
    Mean (SD)                                4.27 (3.04)             2.07 (1.68)             3.66 (2.75)             1.95 (1.55)    
    CCI \< 2                                 32,217        18.73%    879,610       56.82%    88,195        25.64%    823,632       59.86
    CCI ≥ 2                                  139,787       81.27%    668,427       43.18%    255,824       74.36%    552,390       40.14
    Charlson comorbidities                                                                                                          
    Myocardial infarction                    20,594        11.97%    32,411        2.09%     29,040        8.44%     23,965        1.74%
    Congestive heart failure                 36,022        20.94%    84,121        5.43%     55,756        16.21%    64,387        4.68%
    Peripheral vascular disease              21,069        12.25%    68,687        4.44%     34,510        10.03%    55,246        4.01%
    Cardiovascular disease                   31,358        18.23%    109,220       7.06%     53,770        15.63%    86,808        6.31%
    Dementia                                 2,419         1.41%     11,390        0.74%     4,765         1.39%     9,044         0.66%
    Chronic pulmonary disease                49,776        28.94%    213,749       13.81%    89,955        26.15%    173,570       12.61%
    Rheumatological disease                  8,821         5.13%     30,566        1.97%     15,119        4.39%     24,268        1.76%
    Peptic ulcer disease                     5,174         3.01%     13,678        0.88%     8,643         2.51%     10,209        0.74%
    Mild liver disease                       3,654         2.12%     6,305         0.41%     5,380         1.56%     4,579         0.33%
    Diabetes without chronic complications   169,829       98.74%    1,525,023     98.51%    339,677       98.74%    1,355,175     98.48%
    Diabetes with chronic complications      45,140        26.24%    219,433       14.17%    83,992        24.41%    180,581       13.12%
    Paraplegia                               3,765         2.19%     4,538         0.29%     5,139         1.49%     3,164         0.23%
    Renal impairment                         17,789        10.34%    29,344        1.90%     26,180        7.61%     20,953        1.52%
    Cancer                                   34,466        20.04%    101,118       6.53%     54,085        15.72%    81,499        5.92%
    Severe liver disease                     39,130        22.75%    113,367       7.32%     66,117        19.22%    86,380        6.28%
    Metastatic cancer                        9,830         5.71%     7,726         0.50%     12,346        3.59%     5,210         0.38%
    HIV/AIDS                                 1,094         0.64%     2,050         0.13%     1,693         0.49%     1,451         0.11%
  Antidiabetic agents received on Index                                                                                             
    Glucagon-like peptide-1                  991           0.58%     7,500         0.48%     2,390         0.69%     6,101         0.44%
    Dipeptidyl peptidase-4                   629           0.37%     6,071         0.39%     1,291         0.38%     5,409         0.39%
    Biguanides                               21,285        12.37%    218,752       14.13%    46,060        13.39%    193,977       14.10%
    Sulfonylureas                            14,169        8.24%     122,570       7.92%     29,290        8.51%     107,449       7.81%
    Thiazolidinedione                        9,976         5.80%     85,809        5.54%     23,079        6.71%     72,706        5.28%
    Meglitinides                             1,045         0.61%     7,266         0.47%     2,491         0.72%     5,820         0.42%
    Alpha-glucosidase inhibitors             187           0.11%     1,435         0.09%     460           0.13%     1,162         0.08%
    Insulin                                  14,220        8.27%     70,542        4.56%     29,921        8.70%     54,841        3.99%
    Other antidiabetic agents                8,689         5.05%     79,749        5.15%     19,045        5.54%     69,393        5.04%

CCI = Charlson Comorbidity Index; SD = standard deviation.

^a^CCI score calculated in the 1-year post-index date period.

Patients in the top 10% of the cost distribution were found to be similar to patients in the top 20% of the cost distribution in terms of mean age, sex distribution, geographic region, health plan type, and payer type. The mean (SD) CCI score was greater for patients in the top 10% of the cost distribution (4.3 \[3.0\]), with a greater percentage of these patients having nearly all of the individual CCI components, than for patients in the top 20% of the cost distribution (2.1 \[1.7\]). Additionally, approximately the same percentage of patients in the top 10% of the cost distribution received oral antidiabetic medications and insulin as in the top 20% of the cost distribution.

The strongest predictor of being an HC patient (either in the top 20% or top 10% of the cost distribution) was having a CCI score ≥ 2 (odds ratio \[OR\] for top 20% regression vs. top 10% regression: 3.9 vs. 4.9; both *P* \< 0.0001) (Table [2](#T2){ref-type="table"}). Additionally, a diagnosis of renal impairment (OR for top 20% regression vs. top 10% regression: 2.2 vs. 2.4; both *P* \< 0.0001), a diagnosis of obesity (OR for top 20% regression vs. top 10% regression: 2.0 vs. 2.1; both *P* \< 0.0001), receipt of insulin (OR for top 20% regression vs. top 10% regression: 2.7 vs. 2.1; both *P* \< 0.0001), and a diagnosis of hypertension (OR for top 20% regression vs. top 10% regression: 1.5 vs. 1.6; both *P* \< 0.0001) were all found to be associated with a significant increase in the odds of being an HC patient.

###### 

**Predictors of being an HC T2DM patient, among all patients with T2DM**^**a**^

  **Variable**                                                     **Cohort**                                                          
  ---------------------------------------------------------------- ------------ ------- --------- ----------- ------- -------- ------- -----------
  Age, in years (vs. 55+ years)                                                                                                         
    \< 35                                                          1.128        1.098   1.159     \< 0.0001   1.311   1.286    1.337   \< 0.0001
    35-44                                                          1.063        1.043   1.085     \< 0.0001   1.094   1.078    1.110   \< 0.0001
    45-54                                                          1.200        1.184   1.216     \< 0.0001   1.179   1.167    1.191   \< 0.0001
  Female (vs. male)                                                1.023        1.012   1.034     \< 0.0001   1.175   1.165    1.184   \< 0.0001
  Geographic region (vs. East)                                                                                                          
    South                                                          0.814        0.800   0.827     \< 0.0001   0.763   0.754    0.773   \< 0.0001
    Midwest                                                        1.166        1.150   1.183     \< 0.0001   1.156   1.144    1.168   \< 0.0001
    West                                                           1.107        1.088   1.128     \< 0.0001   1.047   1.033    1.062   \< 0.0001
  Health plan type (vs. health maintenance organization)                                                                                
    Preferred provider organization                                1.091        1.074   1.108     \< 0.0001   1.041   1.029    1.054   \< 0.0001
    Point of service                                               1.141        1.119   1.163     \< 0.0001   1.080   1.063    1.096   \< 0.0001
    Indemnity                                                      0.510        0.499   0.521     \< 0.0001   0.608   0.598    0.618   \< 0.0001
  Payer type (vs. commercial)                                                                                                           
    Medicaid                                                       1.221        1.170   1.274     \< 0.0001   1.198   1.157    1.239   \< 0.0001
    Medicare or Medicare Gap                                       1.070        1.050   1.089     \< 0.0001   0.978   0.964    0.992   0.0024
    Self                                                           0.885        0.868   0.902     \< 0.0001   0.967   0.953    0.981   \< 0.0001
  Charlson Comorbidity Index score ≥ 2 (vs. \< 2)                  4.896        4.832   4.961     \< 0.0001   3.908   3.873    3.944   \< 0.0001
  Renal impairment diagnosis (vs. no renal impairment diagnosis)   2.368        2.333   2.404     \< 0.0001   2.179   2.150    2.208   \< 0.0001
  Hypertension diagnosis (vs. no hypertension diagnosis)           1.625        1.602   1.648     \< 0.0001   1.519   1.504    1.535   \< 0.0001
  Obesity diagnosis (vs. no obesity diagnosis)                     2.106        2.076   2.13741   \< 0.0001   2.033   2.009    2.056   \< 0.0001
  Antidiabetic treatment (vs. no treatment)                                                                                             
    Received insulin                                               2.098        2.068   2.128     \< 0.0001   2.744   2.7142   2.775   \< 0.0001
    Received oral antidiabetic agents only                         1.110        1.097   1.124     \< 0.0001   1.283   1.271    1.294   \< 0.0001

CI = confidence interval; HC = high cost; T2DM = type 2 diabetes mellitus.

^a^28,100 patients were excluded from the regression analysis because they were missing age, sex, health plan, or payer information.

Patients in the top 20% of the cost distribution had total all-cause costs that were, on average, \$32,179 more than the costs accrued by patients in the bottom 80% of the cost distribution (mean \[SD\] all-cause costs, top 20% vs. bottom 80%: \$35,596 \[\$50,903\] vs. \$3,417 \[\$2,775\]) (Table [3](#T3){ref-type="table"}). Furthermore, patients in the top 10% of the cost distribution had total all-cause costs that were, on average, \$51,794 more than the costs accrued by patients in the bottom 90% of the cost distribution (i.e., mean \[SD\] all-cause costs, top 10% vs. bottom 90%: \$56,468 \[\$65,604\] vs. \$4,674 \[\$4,504\]. Additionally, all-cause costs for patients in the top 10% of the cost distribution were approximately \$20,872 more than all-cause costs for patients in the top 20% of the cost distribution.

###### 

Summary of overall health care utilization and costs during the 12-month follow-up period, by cohort

                                              **Cohort**                                                                            
  ------------------------------------------- ------------ ------------ ----------- ----------- ---------- ------------ ----------- -----------
  Inpatient services                                                                                                                 
    Had ≥ 1 hospital admission (n, %)         127,553      74.16%       166,729     10.77%      192,070    55.83%       102,212     7.43%
    Had ≥ 2 hospital admissions (n, %)        59,199       34.42%       31,289      2.02%       72,263     21.01%       18,225      1.32%
    Mean number of admissions (SD)            1.44         (1.62)       0.14        (0.45)      0.97       (1.36)       0.09        (0.37)
    Mean (SD) inpatient days^a^               13.81        (24.88)      7.07        (39.57)     11.65      (22.04)      6.89        (49.31)
    Mean (SD) total costs                     \$24,766     (\$48,149)   \$427       (\$1,739)   \$13,618   (\$35,945)   \$171       (\$805)
  SNF stays                                                                                                                          
    Had ≥ 1 SNF admission (n, %)              10,410       6.05%        8,987       0.58%       14,047     4.08%        5,350       0.39%
    Mean number of SNF admissions (SD)        0.10         (0.49)       0.01        (0.14)      0.07       (0.41)       0.01        (0.10)
    Mean (SD) SNF days^a^                     33.70        (44.70)      48.52       (203.18)    42.75      (135.81)     34.84       (157.98)
    Mean (SD) total costs                     \$525        (\$3,532)    \$20        (\$389)     \$323      (\$2,612)    \$7         (\$180)
  ED visits                                                                                                                          
    Had ≥ 1 ED visit (n, %)                   103,348      60.08%       355,475     22.96%      183,931    53.47%       274,892     19.98%
    Mean number of ED visits (SD)             5.31         (14.32)      1.29        (4.60)      4.26       (11.65)      1.05        (3.90)
    Mean (SD) total costs                     \$888        (\$2,283)    \$136       (\$505)     \$659      (\$1,791)    \$99        (\$370)
  Office visits                                                                                                                      
    Had ≥ 1 office visit (n, %)               168,403      97.91%       1,505,071   97.22%      336,935    97.94%       1,336,539   97.13%
    Mean number of office visits (SD)         26.00        (20.97)      12.72       (12.11)     23.73      (19.25)      11.62       (10.86)
    Mean (SD) total costs                     \$5,827      (\$13,092)   \$1,155     (\$1,440)   \$4,246    (\$9,562)    \$967       (\$1,098)
  Pharmacy                                                                                                                           
    Had ≥ 1 prescription (n, %)               150,474      87.48%       1,225,785   79.18%      302,929    88.06%       1,073,330   78.00%
    Mean number of prescriptions (SD)         53.72        (44.11)      27.99       (28.83)     50.37      (41.21)      25.61       (26.56)
    Mean (SD) total costs                     \$4,854      (\$12,486)   \$1,428     (\$2,162)   \$4,190    (\$9,270)    \$1,166     (\$1,660)
  Outpatient hospital visits                                                                                                         
    Had ≥ 1 outpatient visit (n, %)           131,885      76.68%       844,910     54.58%      257,619    74.89%       719,176     52.26%
    Mean number of outpatient visits (SD)     43.33        (82.58)      9.15        (20.37)     32.64      (65.27)      7.55        (16.13)
    Mean (SD) total costs                     \$8,763      (\$22,823)   \$767       (\$1,816)   \$5,807    (\$16,625)   \$507       (\$1,136)
  Laboratory services                                                                                                                
    Had ≥ 1 laboratory service (n, %)         92,529       53.79%       655,781     42.36%      178,840    51.99%       569,470     41.39%
    Mean number of laboratory services (SD)   13.13        (30.85)      5.50        (11.32)     10.72      (24.64)      5.15        (10.57)
    Mean (SD) total costs                     \$247        (\$810)      \$75        (\$210)     \$194      (\$630)      \$66        (\$179)
  OOP services                                                                                                                       
    Had ≥ 1 OOP services (n, %)               153,936      89.50%       834,883     53.93%      293,499    85.31%       695,320     50.53%
    Mean number of OOP services (SD)          46.30        (95.37)      8.49        (22.41)     34.05      (75.59)      6.82        (16.91)
    Mean (SD) total costs                     \$10,598     (\$29,858)   \$666       (\$1,633)   \$6,559    (\$21,633)   \$434       (\$1,016)
  Total health care utilization                                                                                                      
    Had ≥ 1 medical encounter (n, %)          172,004      100.00%      1,548,037   100.00%     344,019    100.00%      1,376,022   100.00%
    Mean number of encounters (SD)            189.33       (150.55)     65.29       (51.82)     156.81     (123.32)     57.92       (42.74)
    Mean (SD) total costs                     \$56,468     (\$65,604)   \$4,674     (\$4,504)   \$35,596   (\$50,903)   \$3,417     (\$2,775)

ED = emergency department; OOP = other outpatient; SD = standard deviation; SNF = skilled nursing facility.

^a^Mean inpatient and SNF days estimated among only those patients with at least 1 unique admission.

All-cause inpatient visits were responsible for approximately 42% of the difference in all-cause costs between patients in the top 20% and patients in the bottom 80% of the cost distribution, with 55.8% of patients in the top 20% of the cost distribution having at least one all-cause hospitalization and 21.0% of patients having two or more hospitalizations compared with 7.4% of patients in the bottom 80% of the cost distribution having at least one all-cause hospitalization and 1.3% of patients having two or more hospitalizations. Similarly, all-cause inpatient visits were responsible for approximately 47% of the difference in costs between patients in the top 10% and patients in the bottom 90% of the distribution, with 74.2% of patients in the top 10% of the distribution having at least one all-cause hospitalization and 34.4% of patients having two or more hospitalizations, compared with only 10.8% of patients in the bottom 90% of the distribution having at least one all-cause hospitalization and 2.0% of patients having two or more hospitalizations.

All-cause outpatient hospital visits contributed to approximately 16.5% of the difference in costs between patients in the top 20% and patients in the bottom 80% of the cost distribution, with 74.9% of patients in the top 20% of the cost distribution having at least one all-cause outpatient hospital visit compared with 52.3% of patients in the bottom 80% of the cost distribution. Outpatient hospital visits had a similar contribution to the difference in costs between patients in the top 10% and patients in the bottom 90% of the cost distribution. Specifically, all-cause outpatient hospital visits contributed to approximately 15.4% of the difference in all-cause costs between patients in the top 10% of the cost distribution and patients in the bottom 90% of the cost distribution, with 76.7% of patients in the top 10% of the cost distribution having at least one all-cause outpatient hospital visit, compared with 54.6% of patients in the bottom 90% of the all-cause cost distribution.

All-cause prescription fills and all-cause office visits contributed to 9.4% and 10.2% of the difference in all-cause costs among patients in the top 20% and bottom 80%, respectively, of the cost distribution. All-cause prescription fills and all-cause office visits contributed to 6.6% and 9.0% of the difference among patients in the top 10% and bottom 90%, respectively, of the cost distribution. However, patients in both the top 20% and top 10% of the cost distribution filled approximately twice as many prescriptions and had almost double the number of physician office visits, compared with patients in the bottom 80% and bottom 90% of the cost distribution (top 20% vs. bottom 80%: 50.4 vs. 25.6 prescription fills; 23.7 vs. 11.6 office visits: top 10% vs. bottom 90%: 53.7 vs. 28.0 prescription fills; 26.0 vs. 12.7 office visits).

Health care costs related to T2DM were, on average, \$2,977 more for patients in the top 20% of the cost distribution than for patients in the bottom 80% of the cost distribution and \$4,136 more for patients in the top 10% of the cost distribution than for patients in the bottom 90% of the cost distribution (Table [4](#T4){ref-type="table"}). Mean (SD) T2DM-related costs among patients in the top 20% of the cost distribution were \$3,780 (\$8,530), which represented 10.6% of all-cause costs; T2DM-related costs among patients in the bottom 80% of the cost distribution were \$803 (\$1,065), which represented 23.5% of all-cause costs. Similarly, mean (SD) T2DM-related costs among patients in the top 10% of the cost distribution were \$5,121 (\$11,575), which represented 9.1% of all-cause costs; T2DM-related costs among patients in the bottom 90% of the cost distribution were \$985 (\$1,469), which represented 21.1% of all-cause costs. Unlike all-cause costs, the biggest difference in T2DM-related costs between patients in the top 20% and 10% and patients in bottom 80% and 90% of the cost distribution was outpatient hospital visits, which accounted for approximately 25% of the cost difference in both groups.The entire T2DM population included in this study (N = 1,720,041) accrued all-cause costs of approximately \$17 billion (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). The top 10% of patients accrued costs of more than \$9.7 billion, which represented more than 57% of the costs accrued by this population. The top 20% of patients accrued costs of more than \$12 billion, which represented more than 72% of the costs accrued by this population. In the overall population of patients, over \$2.4 billion of the total all-cause costs could be directly linked to T2DM (i.e., 14.2% of all-cause costs accrued by this population were attributable directly to T2DM). The top 10% of patients accrued T2DM-related costs of \$880 million, which represented 36.6% of the total T2DM-related costs, while the top 20% of patients accrued T2DM-related costs of \$1.3 billion, which represented 54.1% of the total T2DM-related costs.

###### 

Summary of diabetes-related health care utilization and costs during the 12-month follow-up period, by cohort

                                                   **Cohort**                                                                          
  ------------------------------------------------ ------------ ------------ ----------- ----------- --------- ----------- ----------- -----------
  Diabetes-related inpatient stays                                                                                                      
    Had ≥ 1 hospital admission (n, %)              30,310       17.62%       27,729      1.79%       41,220    11.98%      16,819      1.22%
    Mean number of hospital admissions (SD)        0.23         (0.60)       0.02        (0.15)      0.15      (0.48)      0.01        (0.12)
    Mean (SD) inpatient days^a^                    6.93         (10.48)      4.29        (7.60)      6.28      (9.68)      4.17        (8.16)
    Mean costs (SD)                                \$677        (\$5,515)    \$20        (\$331)     \$387     (\$3,953)   \$10        (\$194)
  Diabetes-related SNF stays (n, %)                                                                                                     
    Had ≥ 1 SNF admission                          1,802        1.05%        1,405       0.09%       2,468     0.72%       739         0.05%
    Mean number of SNF admissions (SD)             0.01         (0.14)       0.00        (0.04)      0.01      (0.12)      0.00        (0.03)
    Mean (SD) SNF days^a^                          12.96        (31.56)      22.29       (139.07)    17.53     (105.76)    15.41       (43.85)
    Mean costs (SD)                                \$14         (\$424)      \$1         (\$76)      \$9       (\$332)     \$0         (\$37)
  Diabetes-related ED visits                                                                                                            
    Had ≥ 1 ED visit (n, %)                        39,813       23.15%       132,909     8.59%       70,699    20.55%      102,023     7.41%
    Mean number of ED visits (SD)                  1.36         (5.88)       0.38        (2.37)      1.14      (5.03)      0.31        (2.07)
    Mean costs (SD)                                \$232        (\$1,003)    \$42        (\$277)     \$182     (\$825)     \$31        (\$204)
  Diabetes-related office visits                                                                                                        
    Had ≥ 1 office visit (n, %)                    137,104      79.71%       1,273,378   82.26%      277,094   80.55%      1,133,388   82.37%
    Mean number of office visits (SD)              4.28         (4.59)       3.42        (3.32)      4.23      (4.39)      3.33        (3.18)
    Mean costs (SD)                                \$469        (\$1,290)    \$245       (\$357)     \$424     (\$1,002)   \$228       (\$314)
  Diabetes-related pharmacy                                                                                                             
    Had ≥ 1 prescription (n, %)                    107,729      62.63%       818,451     52.87%      219,248   63.73%      706,932     51.38%
    Mean number of prescriptions (SD)              6.98         (8.57)       5.49        (7.72)      7.29      (8.78)      5.22        (7.51)
    Mean costs (SD)                                \$636        (\$1,660)    \$356       (\$806)     \$702     (\$1,511)   \$304       (\$694)
  Diabetes-related outpatient hospital visits                                                                                           
    Had ≥ 1outpatient visit (n, %)                 69,070       40.16%       411,072     26.55%      131,277   38.16%      348,865     25.35%
    Mean number of outpatient visits (SD)          6.18         (18.89)      2.46        (7.63)      5.23      (16.47)     2.23        (6.49)
    Mean (SD) total costs                          \$1,204      (\$5,433)    \$145       (\$652)     \$849     (\$4,007)   \$101       (\$408)
  Diabetes-related laboratory services                                                                                                  
    Had ≥ 1 laboratory service (n, %)              51,096       29.71%       439,858     28.41%      101,715   29.57%      389,239     28.29%
    Mean number of laboratory services (SD)        3.52         (9.92)       2.76        (6.48)      3.35      (8.82)      2.71        (6.32)
    Mean (SD) total costs                          \$48         (\$204)      \$29        (\$90)      \$43      (\$169)     \$28        (\$85)
  Diabetes-related OOP services                                                                                                         
    Had ≥ 1 OOP service (n, %)                     80,576       46.85%       414,844     26.80%      147,877   42.99%      347,543     25.26%
    Mean number of OOP services (SD)               8.11         (24.22)      2.29        (7.32)      6.33      (19.66)     2.01        (6.09)
    Mean costs (SD)                                \$1,842      (\$7,754)    \$147       (\$659)     \$1,182   (\$5,634)   \$100       (\$398)
  Diabetes-related total health care utilization                                                                                        
    Had ≥ 1 medical encounter (n, %)               168,326      97.86%       1,541,265   99.56%      338,383   98.36%      1,371,208   99.65%
    Mean number of encounters (SD)                 30.68        (37.16)      16.83       (16.26)     27.72     (31.67)     15.84       (14.58)
    Mean costs (SD)                                \$5,121      (\$11,575)   \$985       (\$1,469)   \$3,780   (\$8,530)   \$803       (\$1,065)

ED = emergency department; OOP = other outpatient; SD = standard deviation; SNF = skilled nursing facility.

^a^Mean inpatient and SNF days estimated among only patients with at least 1 unique admission.

![Descriptive summary of all-cause health care costs during the 12-month follow-up period.](2049-3258-72-6-1){#F1}

![**Descriptive summary of T2DM-related health care costs during the 12-month follow-up period.** T2DM = type 2 diabetes mellitus.](2049-3258-72-6-2){#F2}

Discussion
==========

This study examined patients with T2DM in a large, managed care population and quantified differences in health care costs by categories of cost distributions. Patients were identified as being HC if their total care costs fell in the top 10% or the top 20% of the total cost distribution. Patients in the top 10% of the total cost distribution accrued annual per-patient health care costs that were on average \$50,000 more than the annual per-patient health care costs accrued by patients in the bottom 90% of the total cost distribution. Similarly, patients in the top 20% of the total cost distribution accrued annual per-patient health care costs that were over \$32,000 more than the annual per-patient health care costs accrued by patients in the bottom 80% of the total cost distribution. Multivariable logistic regression models found that patients were significantly more likely to be in the top 10% or the top 20% of the total cost distribution if they had a CCI score ≥ 2; had received a diagnosis of renal impairment, obesity, or hypertension; or were treated with insulin.

Data drawn from the Medical Expenditure Panel Survey have previously shown that a small percentage of patients typically account for a large percentage of health care costs. Specifically, using data from 1999, the survey found that, in the general community population, more than half of the total health care spending was accrued by only 5% of the population \[[@B16]\]. The Olin study supports the rule of thumb that 20% of patients consume 80% of health care resources. Additionally, Conwell and Cohen, using data from a 2002 US noninstitutionalized population, found that exactly 20% of patients accrued 80% of costs \[[@B14]\]. Similarly, we found that patients in the top 20% of the total cost distribution accrued costs of \$12.2 billion annually, which represented 72% of the total costs accrued by the T2DM population. Additionally, we found that patients in the top 10% of the total cost distribution accrued costs of \$9.7 billion annually, which represented 57% of the total costs accrued by the T2DM population.

This study used methodology similar to the approach described by Etemad and McCollam in an article examining predictors of HC managed care patients with acute coronary syndrome \[[@B13]\]. Etemad and McCollam identified patients with newly onset acute coronary syndrome and assessed these patients' health care costs over 12 months after disease onset. The authors classified patients as being HC if the patients accrued costs in the top 20% of the population; multivariable regression analyses were estimated to assess predictors of being an HC patient. Similar to our study, many of the factors associated with being an HC patient in the Etemad analysis were nonmodifiable comorbidities such as hypertension, diabetes, or pulmonary disease.

Etemad and McCollam also observed that an initial hospitalization for acute coronary syndrome had costs that were equal to nearly two-thirds of the costs accrued in the entire year following hospital discharge. Although our study used a slightly different methodology (we examined all inpatient stays vs. a single initial inpatient stay) to that of Etemad and McCollam, we found that approximately 40% of the health care costs accrued in HC patients were associated with inpatient visits.

Hartmann \[[@B17]\] examined patients in the top decile of health care spending, using German health insurance information. Consistent with our analysis, Hartmann found that the highest health care expenses for patients were incurred in the inpatient sector, with over 80% of all HC patients having at least one hospital admission (compared with 74.2% in our analysis) \[[@B17]\]. Additionally, Hartmann \[[@B17]\] found that the reasons for the hospitalization differed based on patient age and sex, which further highlights the facts that HC patients require care tailored to their unique situation and that no single intervention exists that will reduce health care costs among all patients.

A previous study examining Medicare patients with T2DM found that interventions aimed at diabetes have not differed based on comorbid illness burden \[[@B18]\]. Our analysis found that patients with a higher comorbidity burden and more concomitant conditions were significantly more likely to be HC. Therefore, from the perspective of a payer, one practical implication of the present analysis is that it may make sense to provide those patients who have the most comorbidities and concomitant conditions (i.e., those patients who are at the greatest risk of being HC) with additional patient care tailored at treating the comorbidity or concomitant condition (e.g., weight loss programs for obese patients).

Sensitivity analyses were conducted, examining the 926,180 patients who received an antidiabetic medication (i.e., either an oral antidiabetic or insulin). In this subpopulation of treated T2DM patients, those with costs greater than \$22,646 comprised the top 10th percentile (vs. \$20,528 in the overall T2DM population), while patients with costs greater than \$12,349 comprised the top 20th percentile (vs. \$10,901 in the overall T2DM population). We found that there were no differences in patient demographics between the overall study sample and those patients who received antidiabetic medication. Predictors of being an HC T2DM patient were the same for the treated and overall T2DM populations. Specifically, in the treated T2DM population, having a CCI score greater than or equal to 2 was the strongest predictor of being an HC patient (OR = 4.862; *P* \< 0.001), followed by a renal impairment diagnosis (OR = 2.369; *P* \< 0.001), an obesity diagnosis (OR = 1.991; *P* \< 0.001), or receipt of insulin (OR = 1.897; *P* \< 0.001). Treated patients in the top 10% of the cost distribution accrued approximately \$53,917 more in health care costs versus treated patients in the bottom 90% of the cost distribution (vs. \$51,794 more in costs in the overall T2DM population), with the largest difference in costs attributable to inpatient stays. Additionally, treated patients in the top 10% of the cost distribution accrued costs of over \$5.5 billion, which represented 54.1% of all costs accrued by the treated T2DM population (vs. 57.3% among all T2DM patients). Treated patients in the top 20% of the cost distribution accrued costs of over \$7.0 billion, which represented 69.0% of all costs accrued by the treated T2DM population (vs. 72.3% among all T2DM patients).

This study has several limitations common to most retrospective database studies. First, it was not possible to confirm diagnoses for T2DM, renal impairment, hypertension, or obesity. No laboratory data were available to further assess the level of renal impairment, and no information was available in the database regarding patients' height or weight. Thus, rates of obesity and renal impairment reported in the analysis are likely underestimated. Additionally, no information was available regarding blood glucose or glycated hemoglobin values, so the effect of glucose control on costs could not be assessed. Logistic regression model specifications were limited to the data available, and additional predictors of being an HC patient may exist (e.g., increased glycated hemoglobin value). Because this study used retrospective administrative claims, it was not feasible to assess the effect of an intervention (e.g., change in diabetes medication) on costs. Further, because our study used data from a managed care population, results may not be applicable to Medicaid, Medicare, or uninsured patients.

The goal of this study was to provide payers with a means of identifying patients who are at increased risk for becoming HC, using real-world data. Once these patients are identified, personalized interventions could be developed that may decrease the likelihood of the patient becoming HC. Interventions might include extra office visits for comorbid conditions, structured weight loss programs, or increased pharmacotherapy for glucose control. Economic evaluations to examine the cost-benefit structure of developing such interventions would be informative.

Conclusions
===========

This study examined health care resource utilization and costs in a large, real-world, managed care population. In conclusion, it was found that patients with T2DM who make up the top 10% of a cost distribution for T2DM accrue, on average, 12 times more total annual health care costs than patients who make up the bottom 90% of the cost distribution. Further, T2DM patients who make up the top 20% of the cost distribution accrue, on average, 11 times more health care costs than patients who make up the bottom 80% of the cost distribution. Obesity and progression to insulin were found to predict the odds of being an HC patient and are two modifiable factors for T2DM patients. Further research is needed to explore potential interventions to reduce the likelihood that a patient becomes HC. Our study also found that cost of a hospitalization was the largest component of HC patients' total care costs. Reducing all-cause hospitalizations in patients with T2DM through interventions aimed at better management of T2DM (e.g., outpatient management, lifestyle changes) may help to reduce costs.
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